|Integrative clinical genomics of advanced prostate cancer|
D Robinson, EM Van Allen, YM Wu, N Schultz, RJ Lonigro, JM Mosquera, ...
Cell 161 (5), 1215-1228, 2015
|DNA-repair defects and olaparib in metastatic prostate cancer|
J Mateo, S Carreira, S Sandhu, S Miranda, H Mossop, R Perez-Lopez, ...
New England Journal of Medicine 373 (18), 1697-1708, 2015
|Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage …|
ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ...
The Lancet 387 (10024), 1163-1177, 2016
|Abiraterone for prostate cancer not previously treated with hormone therapy|
ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ...
New England Journal of Medicine 377 (4), 338-351, 2017
|Re: Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostrate cancer commonly remains hormone driven|
G Attard, AH Reid, TA Yap, F Raynaud, M Dowsett
Journal of clinical oncology 26 (28), 4563-4571, 2008
|Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial|
CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ...
The Lancet 392 (10162), 2353-2366, 2018
|Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017|
S Gillessen, G Attard, TM Beer, H Beltran, A Bossi, R Bristow, B Carver, ...
European urology 73 (2), 178-211, 2018
|Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer|
G Attard, AHM Reid, R A’Hern, C Parker, NB Oommen, E Folkerd, ...
Journal of clinical oncology: official journal of the American Society of …, 2009
|Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer|
G Attard, JF Swennenhuis, D Olmos, AHM Reid, E Vickers, R A'Hern, ...
Cancer research 69 (7), 2912-2918, 2009
|Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer|
G Attard, J Clark, L Ambroisine, G Fisher, G Kovacs, P Flohr, D Berney, ...
Oncogene 27 (3), 253-263, 2008
|Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate|
AHM Reid, G Attard, DC Danila, NB Oommen, D Olmos, PC Fong, ...
Journal of clinical oncology 28 (9), 1489, 2010
|Plasma AR and abiraterone-resistant prostate cancer|
A Romanel, DG Tandefelt, V Conteduca, A Jayaram, N Casiraghi, ...
Science translational medicine 7 (312), 312re10-312re10, 2015
|Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100)|
Y Loriot, D Bianchini, E Ileana, S Sandhu, A Patrikidou, C Pezaro, ...
Annals of oncology 24 (7), 1807-1812, 2013
|Circulating tumor cell biomarker panel as an individual-level surrogate for survival in metastatic castration-resistant prostate cancer|
HI Scher, G Heller, A Molina, G Attard, DC Danila, X Jia, W Peng, ...
Journal of clinical oncology 33 (12), 1348, 2015
|Tumor clone dynamics in lethal prostate cancer|
S Carreira, A Romanel, J Goodall, E Grist, R Ferraldeschi, S Miranda, ...
Science translational medicine 6 (254), 254ra125-254ra125, 2014
|Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015|
S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ...
Annals of Oncology 26 (8), 1589-1604, 2015
|Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial|
NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ...
Annals of Oncology 30 (12), 1992-2003, 2019
|Molecular characterisation of ERG, ETV1 and PTEN gene loci identifies patients at low and high risk of death from prostate cancer|
AHM Reid, G Attard, L Ambroisine, G Fisher, G Kovacs, D Brewer, J Clark, ...
British journal of cancer 102 (4), 678-684, 2010
|Steroid hormone receptors in prostate cancer: a hard habit to break?|
G Attard, CS Cooper, JS de Bono
Cancer cell 16 (6), 458-462, 2009
|Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers|
R Plummer, G Attard, S Pacey, L Li, A Razak, R Perrett, M Barrett, ...
Clinical cancer research 13 (20), 6187-6194, 2007